Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Durysta
- Development stage
- Unknown
- Lead developer
- AbbVie
- Modality
- Small Molecules
- Administration
- Ophthalmic
01
Overview
Durysta (bimatoprost sustained-release implant) is a sterile, biodegradable intracameral implant developed by AbbVie (following its acquisition of Allergan) for the reduction of intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension. The implant consists of a solid polymer matrix (PLGA) that slowly degrades to release bimatoprost, a prostaglandin analog and prostamide receptor agonist, directly into the anterior chamber of the eye. Bimatoprost lowers IOP by increasing the outflow of aqueous humor through both the trabecular meshwork and uveoscleral pathways. This sustained-release delivery system is designed to provide continuous therapeutic effect for several months, potentially addressing the clinical challenge of patient non-adherence to daily topical eye drop regimens. The Phase 3 ATHENA study compared the efficacy and safety of Durysta to selective laser trabeculoplasty (SLT), confirming its role as a potent alternative to traditional glaucoma therapies.
- Brand names
- Durysta
- Other names
- Bimatoprost SRBimatoprost sustained-release implantBimatoprost intracameral implant
02
Targets
PTGFR (Prostaglandin F2 alpha receptor)
Beyond the preview
Go deeper on Durysta.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Durysta.